The genetic engineering of hematopoietic stem cells: The rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors

Molecular Therapy

Volumn 15, Issue 3, 2007, Pages 445-456

  Chang, Alex H ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; BLOOD CLOTTING FACTOR 9; CARMUSTINE; LENTIVIRUS VECTOR; PHOSPHOGLYCERATE KINASE; PROTEASOME INHIBITOR; RETROVIRUS VECTOR; WISKOTT ALDRICH SYNDROME PROTEIN;

BETA THALASSEMIA; CARCINOGENESIS; CELL BASED GENE THERAPY; CELL LINEAGE; COMBINED IMMUNODEFICIENCY; ENGRAFTMENT; ENZYME DEFICIENCY; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; GENOMIC INSTABILITY; GENOTOXICITY; HEMATOPOIETIC STEM CELL; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LONG TERMINAL REPEAT; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SAFETY; SICKLE CELL ANEMIA; TISSUE SPECIFICITY; TRANSGENE; WISKOTT ALDRICH SYNDROME;

ANIMALS; CELL LINEAGE; GENETIC ENGINEERING; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HIV LONG TERMINAL REPEAT; HUMANS; LENTIVIRUS;

EID: 33847205752     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300060     Document Type: Review

References (232)

1. Dunbar, CE (1996). Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Annu Rev Med 47: 11-20.
2. Ballas, CB, Zielske, SP and Gerson, SL (2002). Adult bone marrow stem cells for cell and gene therapies: Implications for greater use. J Cell Biochem Suppl 38: 20-28.
3. Engel, BC and Kohn, DB (2003). Gene therapy for inborn and acquired immune deficiency disorders. Acta Haematol 110: 60-70.
4. Hargrove, PW, Vanin, EF, Kurtzman, GJ and Nienhuis, AW (1997). High-level globin gene expression mediated by a recombinant adeno-associated virus genome that contains the 3′-γ globin gene regulatory element and integrates as tandem copies in erythroid cells. Blood 89: 2167-2175.
5. Srivastava, A (2005). Hematopoietic stem cell transduction by recombinant adeno-associated virus vectors: Problems and solutions. Hum Gene Ther 16: 792-798.
6. Olivares, EC, Hollis, RP, Chalberg, TW, Meuse, L, Kay, MA and Calos, MP (2002). Site-specific genomic integration produces therapeutic factor IX levels in mice. Nat Biotechnol 20: 1124-1128.
7. Essner, JJ, McIvor, RS and Hackett, PB (2005). Awakening gene therapy with Sleeping Beauty transposons. Curr Opin Pharmacol 5: 513-519.
8. Urnov, FD et al. (2005). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435: 646-651.
9. Chen, L and Woo, SL (2005). Complete and persistent phenotypic correction of phenylketonuria in mice by site-specific genome integration of murine phenylalanine hydroxylase cDNA. Proc Natl Acad Sci USA 102: 15581-15586.
10. Kohn, DB et al. (2003). American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 8: 180-187.
11. Naldini, L et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
12. Sutton, RE, Wu, HT, Rigg, R, Bohnlein, E and Brown, PO (1998). Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J Virol 72: 5781-5788.
13. 1 human hematopoietic stem cells. Proc Natl Acad Sci USA 95: 11939-11944.
14. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283: 682-686.
15. - human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 96: 2988-2993.
16. May, C et al. (2000). Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 406: 82-86.
17. Mergia, A and Heinkelein, M (2003). Foamy virus vectors. Curr Top Microbiol Immunol 277: 131-159.
18. Vassilopoulos, G, Trobridge, G, Josephson, NC and Russell, DW (2001). Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors. Blood 98: 604-609.
19. Trobridge, GD et al. (2006). Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 103: 1498-1503.
20. Boggs, DR, Saxe, DF and Boggs, SS (1984). Aging and hematopoiesis. II. The ability of bone marrow cells from young and aged mice to cure and maintain cure in W/Wv. Transplantation 37: 300-306.
21. Szilvassy, SJ, Humphries, RK, Lansdorp, PM, Eaves, AC and Eaves, CJ (1990). Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. Proc Natl Acad Sci USA 87: 8736-8740.
22. Benveniste, P, Cantin, C, Hyam, D and Iscove, NN (2003). Hematopoietic stem cells engraft in mice with absolute efficiency. Nat Immunol 4: 708-713.
23. Bradford, GB, Williams, B, Rossi, R and Bertoncello, I (1997). Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp Hematol 25: 445-453.
24. Mahmud, N et al. (2001). The relative quiescence of hematopoietic stem cells in nonhuman primates. Blood 97: 3061-3068.
25. Cheshier, SH, Morrison, SJ, Liao, X and Weissman, IL (1999). In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci USA 96: 3120-3125.
26. Nash, R, Storb, R and Neiman, P (1988). Polyclonal reconstitution of human marrow after allogeneic bone marrow transplantation. Blood 72: 2031-2037.
27. Abkowitz, JL et al. (1995). Behavior of hematopoietic stem cells in a large animal. Proc Natl Acad Sci USA 92: 2031-2035.
28. Rufer, N et al. (1999). Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 190: 157-167.
29. Kim, HJ et al. (2000). Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. Blood 96: 1-8.
30. Lewis, PF and Emerman, M (1994). Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68: 510-516.
31. 1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 72: 3161-3168.
32. Bukrinsky, MI et al. (1993). A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365: 666-669.
33. Gallay, P, Swingler, S, Aiken, C and Trono, D (1995). HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 80: 379-388.
34. Heinzinger, NK et al. (1994). The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 91: 7311-7315.
35. Popov, S, Rexach, M, Ratner, L, Blobel, G and Bukrinsky, M (1998). Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 273: 13347-13352.
36. Gallay, P, Hope, T, Chin, D and Trono, D (1997). HIV-1 infection of nondividing cells through the recognition of integrase by the importin/ karyopherin pathway. Proc Natl Acad Sci USA 94: 9825-9830.
37. Goff, SP (2001). Intracellular trafficking of retroviral genomes during the early phase of infection: Viral exploitation of cellular pathways. J Gene Med 3: 517-528.
38. Zufferey, R, Nagy, D, Mandel, RJ, Naldini, L and Trono, D (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875.
39. Sirven, A et al. (2000). The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96: 4103-4110.
40. Follenzi, A, Ailles, LE, Bakovic, S, Geuna, M and Naldini, L (2000). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25: 217-222.
41. Zennou, V, Petit, C, Guetard, D, Nerhbass, U, Montagnier, L and Charneau, P (2000). HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101: 173-185.
42. Yamashita, M and Emerman, M (2005). The cell cycle independence of HIV infections is not determined by known karyophilic viral elements. PLoS Pathog 1: E18.
43. - cell transduction via lentivirus-based gene transfer vectors. Hum Gene Ther 10: 1479-1489.
44. - bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol Ther 1: 566-573.
45. Sutton, RE, Reitsma, MJ, Uchida, N and Brown, PO (1999). Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol 73: 3649-3660.
46. Korin, YD and Zack, JA (1999). Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol 73: 6526-6532.
47. Zack, JA, Arrigo, SJ, Weitsman, SR, Go, AS, Haislip, A and Chen, IS (1990). HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 61: 213-222.
48. Zack, JA, Haislip, AM, Krogstad, P and Chen, IS (1992). Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 66: 1717-1725.
49. Dao, MA, Taylor, N and Nolta, JA (1998). Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Proc Natl Acad Sci USA 95: 13006-13011.
50. Cheng, T et al. (2000). Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287: 1804-1808.
51. Stier, S et al. (2003). Ex vivo targeting of p21Cip1/Waf1 permits relative expansion of human hematopoietic stem cells. Blood 102: 1260-1266.
52. Zhang, J, Attar, E, Cohen, K, Crumpacker, C and Scadden, D (2005). Silencing p21(Waf1/Cip1/Sdi1) expression increases gene transduction efficiency in primitive human hematopoietic cells. Gene Ther 12: 1444-1452.
53. Habibian, HK et al. (1998). The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit. J Exp Med 188: 393-398.
54. + cells in non-obese diabetic/severe combined immune-deficient mice. Blood 92: 2641-2649.
55. Dao, MA, Hashino, K, Kato, I and Nolta, JA (1998). Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. Blood 92: 4612-4621.
56. 0. Blood 96: 4185-4193.
57. + cells in the NOD/SCID model. Blood 103: 2079-2087.
58. Kuramoto, K et al. (2004). Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. Blood 103: 4070-4077.
59. Ferguson, C, Larochelle, A and Dunbar, CE (2005). Hematopoietic stem cell gene therapy: Dead or alive? Trends Biotechnol 23: 589-597.
60. Fleming, WH, Alpern, EJ, Uchida, N, Ikuta, K and Weissman, IL (1993). Steel factor influences the distribution and activity of murine hematopoietic stem cells in vivo. Proc Natl Acad Sci USA 90: 3760-3764.
61. Dunbar, CE et al. (1996). Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 93: 11871-11876.
62. de Revel, T et al. (1994). Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 83: 3795-3799.
63. Andrews, RG, Briddell, RA, Knitter, GH, Rowley, SD, Appelbaum, FR and McNiece, IK (1995). Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 85: 15-20.
64. Glaspy JA et al. (1997). Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 90: 2939-2951.
65. -L mobilized cells in nonhuman primates. Blood 101: 2199-2205.
66. Fruehauf, S, Seeger, T and Topaly, J (2005). Innovative strategies for PBPC mobilization. Cytotherapy 7: 438-446.
67. Nassar, N, Cancelas, J, Zheng, J, Williams, DA and Zheng, Y (2006). Structure-function based design of small molecule inhibitors targeting Rho family GTPases. Curr Top Med Chem 6: 1109-1116.
68. Mazurier, F, Gan, OI, McKenzie, JL, Doedens, M and Dick JE (2004). Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment Blood 103: 545-552.
69. Zielske, SP and Braun, SE (2004). Cytokines: Value-added products in hematopoietic stem cell gene therapy. Mol Ther 10: 211-219.
70. Ailles, L et al. (2002). Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells. Mol Ther 6: 615-626.
71. Hom, PA et al. (2004). Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood 103: 3710-3716.
72. Hanawa, H et al. (2004). Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 103: 4062-4069.
73. Hematti, P et al. (2004). Distinct genomic integration of MLV and SIV vectors in Primate hematopoietc stem and progenitor cells. PLoS Biol 2: e423.
74. Mostoslavsky, G, Kotton, DN, Fabian, AJ, Gray, JT, Lee, JS and Mulligan, RC (2005). Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol Ther 11: 932-940.
75. + cells, using a short serum-free transduction protocol. Hum Gene Ther 17: 780-794.
76. - cells from mobilized peripheral blood after cytokine prestimulation. Stem Cells 21: 472-480.
77. Zielske, SP and Gerson, SL (2003). Cytokines, including stem cell factor alone, enhance lentiviral transduction in nondividing human LTCIC and NOD/SCID repopulating cells. Mol Ther 7: 325-333.
78. Logan, AC, Nightingale, SJ, Haas, DL, Cho, GJ, Pepper, KA and Kohn, DB (2004). Factors influencing the titer and infectivity of lentiviral vectors. Hum Gene Ther 15: 976-988.
79. Logan, AC, Lutzko, C and Kohn, DB (2002). Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr Opin Biotechnol 13: 429-436.
80. Santoni de Sio, FR, Cascio, P, Zingale, A, Gasparini, M and Naldini, L (2006). Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 107: 4257-4265.
81. - cells with preserved ability to engraft SCID-hu bone. Blood 91: 1206-1215.
82. - bone marrow long-term culture-initiating cells (LTC-IC), extended LTC-IC, and murine in vivo long-term reconstituting stem cells. Blood 94: 4093-4102.
83. Wognum, AW, Visser, TP, Peters, K, Bierhuizen, MF and Wagemaker, G (2000). Stimulation of mouse bone marrow cells with kit ligand, FLT3 ligand, and thrombopoietin leads to efficient retrovirus-mediated gene transfer to stem cells, whereas interleukin 3 and interleukin 11 reduce transduction of short- and long-term repopulating cells. Hum Gene Ther 11: 2129-2141.
84. + cells (Abstract). Blood 96: 43a.
85. + stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 15: 659-669.
86. Moore, MA (2005). Converging pathways in leukemogenesis and stem cell self-renewal. Exp Hematol 33: 719-737.
87. Verhoeyen, E et al. (2005). Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood 106: 3386-3395.
88. Schwartz, O, Marechal, V, Friguet, B, Arenzana-Seisdedos, F and Heard, JM (1998). Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 72: 3845-3850.
89. Butler, SL, Johnson, EP and Bushman, FD (2002). Human immunodeficiency virus cDNA metabolism: Notable stability of two-long terminal repeat circles. J Virol 76: 3739-3747.
90. Goff, SP (2004). Retrovirus restriction factors. Mol Cell 16: 849-859.
91. Bieniasz, PD (2004). Intrinsic immunity: A front-line defense against viral attack. Nat Immunol 5: 1109A-1115.
92. Peled, A et al. (1999). Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283: 845-848.
93. Christopherson II, KW, Hangoc, G, Mantel, CR and Broxmeyer, HE (2004). Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305: 1000-4003.
94. + progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 103: 2942-2949.
95. Tian, C, Bagley, J, Forman, D and Iacomini, J (2006). Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther 13: 652-658.
96. + cells with HIV-1-derived lentiviral vectors. Mol Ther 2: 71-80.
97. + cells. Mol Ther 3: 359-367.
98. Yokota, T et al. (1998). Growth-supporting activities of fibronectin on hematopoietic stem/progenitor cells in vitro and in vivo: Structural requirement for fibronectin activities of CS1 and cell-binding domains. Blood 91: 3263-3272.
99. Sellers, SE, Tisdale, JF, Agricola, BA, Donahue, RE and Dunbar, CE (2004). The presence of the carboxy-terminal fragment of fibronectin allows maintenance of non-human primate long-term hematopoietic repopulating cells during extended ex vivo culture and transduction. Exp Hematol 32: 163-170.
100. Kang, EM et al. (2006). Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Exp Hematol 34: 132-139.
101. Kahl, CA et al. (2006). Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp Hematol 34: 369-381.
102. Rohdewohld H, Wriker, H, Reik, W, Jaenisch, R and Breindl, M (1987). Retrovirus integration and chromatin structure: Mobney murine leukemia proviral integration sites map near DNAse I-hypersensitive sites. J Virol 61: 336-343.
103. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
104. Mitchell, RS et al. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2: E234.
105. Baum, C, Schambach, A, Bohne, J and Galla, M (2006). Retrovirus vectors: toward the plentivirus? Mol Ther 13: 1050-1063.
106. Zaiss, AK, Son, S and Chang, LJ (2002). RNA 3∓ readthrough of oncoretrovirus and lentivirus: Implications for vector safety and efficacy. J Virol 76: 7209-7219.
107. Morishita, K, Parker, DS, Mucenski, ML, Jenkins, NA, Copeland, NG and Ihle, JN (1988). Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54: 831-840.
108. Montini, E et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
109. Laufs, S, Nagy, KZ, Giordano, FA, Hotz-Wagenblatt, A, Zeller, WJ and Fruehauf, S (2004). Inserdon of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol Ther 10: 874-881.
110. Kohn, DB, Sadelain, M and Glorioso, JC (2003). Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 3: 477-488.
111. De Palma, M et al. (2005). Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105: 2307-2315.
112. Nienhuis, AW, Dunbar, CE and Sorrentino, BP (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13: 1031-1049.
113. Li, Z et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
114. Calmels, B et al. (2005). Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 106: 2530-2533.
115. Seggewiss, R et al. (2006). Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 107: 3865-3867.
116. Ott, MG et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
117. Nucifora, G, Laricchia-Robbio, L and Senyuk, V (2006). EVI1 and hematopoietic disorders: History and perspectives. Gene 368: 1-11.
118. Baum, C et al. (2003). Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101: 2099-2114.
119. Suzuki, T et al. (2002). New genes involved in cancer identified by retroviral tagging. Nat Genet 32: 166-174.
120. Uren, AG, Kool, J, Berns, A and van Lohuizen, M (2005). Retroviral insertional mutagenesis: Past, present and future. Oncogene 24: 7656-7672.
121. Hacein-Bey-Abina, S et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
122. Modlich, U et al, (2006). Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553.
123. Recchia, A et al. (2006). The Influence of Vector Design on Integration Site Selection by gamma-Retroviral and Lentiviral Vectors. Mol. Ther. American Society of Gene Therapy: Baltimore, 13.
124. Woods, NB et al. (2000). Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. Blood 96: 3725-3733.
125. Cherry, SR, Biniszkiewicz, D, Van Parijs, L, Baltimore, D and Jaenisch, R (2000). Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol Cell Biol 20: 7419-7426.
126. Klug, CA, Cheshier, S and Weissman, IL (2000). Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood 96: 894-901.
127. Mohamedali, A, Moreau-Gaudry, F, Richard, E, Xia, P, Nolta, J and Malik, P (2004). Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells. Mol Ther 10: 249-259.
128. Dalle, B et al. (2005). eGFP reporter genes silence LCRbeta-globin transgene expression via CpG dinucleotides. Mol Ther 11: 591-599.
129. Salmon, P, Kindler, V, Ducrey, O, Chapuis, B, Zubler, RH and Trono, D (2000). High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96: 3392-3398.
130. Ramezani, A, Hawley, TS and Hawley, RG (2000). Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther 2: 458-469.
131. Demaison, C et al. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of immunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803-813.
132. Mikkola, H et al. (2000). Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells. J Virol 74: 11911-111918.
133. +-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther 3: 438-448.
134. Hoeben, RC, Einerhand, MP, Briet, E, van Ormondt, H, Valerio, D and van der Eb, AJ (1992). Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 67: 341-345.
135. Evans, GL and Morgan, RA (1998). Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci USA 95: 5734-5739.
136. Moayeri, M, Ramezani, A, Morgan, RA, Hawley, TS and Hawley, RG (2004). Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther 10: 892-902.
137. Kootstra, NA, Matsumura, R and Verma, IM (2003). Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther 7: 623-631.
138. Tiede, A et al. (2003). Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther 10: 1917-1925.
139. + cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice. J Gene Med 6:1049-1060.
140. Bigger, BW et al. (2006). Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther 13: 117-126.
141. Chang, AH, Stephen, MT and Sadelain, M (2006). Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol 24: 1017-1021.
142. Ellis, J (2005). Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 16: 1241-1246.
143. Teich, NM, Weiss, RA, Martin, GR and Lowy, DR (1977). Virus infection of murine teratocarcinoma stem cell lines. Cell 12: 973-982.
144. Speers, WC, Gautsch, JW and Dixon, FJ (1980). Silent infection of murine embryonal carcinoma cells by Moloney murine leukemia virus. Virology 105: 241-244.
145. Osborne, CS, Pasceri, P, Singal, R, Sukonnik, T, Ginder, GO and Ellis, J (1999). Amelioration of retroviral vector silencing in locus control region β-globin-transgenic mice and transduced F9 embryonic cells. J Virol 73: 5490-5496.
146. Rivella, S, Callegari, JA, May, C, Tan, CW and Sadelain, M (2000). The cHS4 insulator increases the probability of retroviral expression at random chromosomal íntegration sites. J Virol 74: 4679-4687.
147. Hanazono, Y, Asano, T, Ueda, Y and Ozawa, K (2003). Genetic manipulation of primate embryonic and hematopoietic stem cells with simian lentivirus vectors. Trends Cardiovasc Med 13: 106-110.
148. Swindle, CS, Kim, HG and Klug, CA (2004). Mutation of CpGs in the murine stem cell virus retroviral vector long terminal repeat represses silencing in embryonic stem cells. J Biol Chem 279: 34-41.
149. Yao, S, Sukonnik, T, Kean, T, Bharadwaj, RR, Pasceri, P and Ellis, J (2004). Retrovirus silencing, variegation, extinction, and memory are controlled by a dynamic interplay of multiple epigenetic modifications. Mol Ther 10: 27-36.
150. Niwa, O, Yokota, Y, Ishida, H and Sugahara, T (1983). Independent mechanisms involved in suppression of the Moloney leukemia virus genome during differentiation of murine teratocarcinoma cells. Cell 32: 1105-1113.
151. Laker, C et al. (1998). Host cis-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation. J Virol 72: 339-348.
152. Pfeifer, A, Ikawa, M, Dayn, Y and Verma, IM (2002). Transgenesis by lentiviral vectors: Lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci USA 99: 2140-2145.
153. Lois, C, Hong, EJ, Pease, S, Brown, EJ and Baltimore, D (2002). Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295: 868-872.
154. Ikawa, M, Tanaka, N, Kao, WW and Verma, IM (2003). Generation of transgenic mice using lentiviral vectors: A novel preclinical assessment of lentiviral vectors for gene therapy. Mol Ther 8: 666-673.
155. Barrette, S, Douglas, JL, Seidel, NE and Bodine, DM (2000). Lentivirus-based vectors transduce mouse hematopoietic stem cells with similar efficiency to moloney murine leukemia virus-based vectors. Blood 96: 3385-3391.
156. Pannell, D et al. (2000). Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J 19: 5884-5894.
157. Woods, NB, Ooka, A and Karlsson, S (2002). Development of gene therapy for hematopoietic stem cells using lentiviral vectors. Leukemia 16: 563-569.
158. Hamaguchi, I et al. (2000). Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J Virol 74: 10778-10784.
159. Schambach, A et al. (2006). Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O(6)-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 13: 391-400.
160. Zufferey, R et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.
161. Dull, T et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.
162. Riviere, I, Brose, K and Mulligan, RC (1995). Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 92: 6733-6737.
163. Armentano, D, Yu, SF, Kantoff, PW, von Ruden, T, Anderson, WF and Gilboa, E (1987). Effect of internal viral sequences on the utility of retroviral vectors. J Virol 61: 1647-1650.
164. Huang, ZM and Yen, TS (1994). Hepatitis B virus RNA element that facilitates accumulation of surface gene transcripts in the cytoplasm. J Virol 68: 3193-3199.
165. Donello, JE, Loeb, JE and Hope, TJ (1998). Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 72: 5085-5092.
166. Loeb, JE, Weitzman, MD and Hope, TJ (2002). Enhancement of green fluorescent protein expression in adeno-associated virus with the Woodchuck hepatitis virus post-transcriptional regulatory element Methods Mol Biol 183: 331-340.
167. Zufferey, R, Donello, JE, Trono, D and Hope, TJ (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886-2892.
168. Schambach, A, Wodrich, H, Hildinger, M, Bohne, J, Krausslich, HG and Baum, C (2000). Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2: 435-445.
169. Kingsman, SM, Mitrophanous, K and Olsen, JC (2005). Potential oncogene activity of the Woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther 12: 3-4.
170. Schambach, A et al. (2006). Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther 13: 641-645.
171. Rivella, S and Sadelain, M (1998). Genetic treatment of severe hemoglobinopathies: The combat against transgene variegation and transgene silencing. Semin Hematol 35: 112-125.
172. Emery, DW and Stamatoyannopoulos, G (1999). Stem cell gene therapy for the beta-chain hemoglobinopathies. Problems and progress. Ann N Y Acad Sci 872: 94-107; Discussion 107-108.
173. Sinn, PL, Sauter, SL and McCray, PB Jr (2005). Gene therapy progress and prospects: Development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther 12: 1089-1098.
174. West, AG, Gaszner, M and Felsenfeld, G (2002). Insulators: Many functions, many mechanisms. Genes Dev 16: 271-288.
175. Recillas-Targa, F et al. (2002). Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci USA 99: 6883-6888.
176. West, AG, Huang, S, Gaszner, M, Litt, MD and Wsenfeld, G (2004). Recruitment of histone modifications by USF proteins at a vertebrate barrier element. Mol Cell 16: 453-463.
177. Emery, DW, Yannaki, E, Tubb, J and Stamatoyannopoulos, G (2000). A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci USA 97: 9150-9155.
178. Yannaki, E, Tubb, J, Aker, M, Stamatoyannopoulos, G and Emery, DW (2002). Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors. Mol Ther 5: 589-598.
179. Ramezani, A, Hawley, TS and Hawley, RG (2003). Performance- and safety-enhanced lentiviral vectors containing the human interferon-β scaffold attachment region and the chicken β-globin insulator. Blood 101: 4717-4724.
180. Bode, J et al. (1992). Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science 255: 195-197.
181. Namciu, SJ, Blochlinger, KB and Fournier, RE (1998). Human matrix attachment regions insulate transgene expression from chromosomal position effects in Drosophila melanogaster. Mol Cell Biol 18: 2382-2391.
182. Bode, J, Benham, C, Knapp, A and Mielke, C (2000). Transcriptional augmentation: Modulation of gene expression by scaffold/matrix-attached regions (S/MAR elements). Crit Rev Eukaryot Gene Exp 10: 73-90.
183. Agarwal, M, Austin, TW, Morel, F, Chen, I, Bohnlein, E and Plavec, I (1998). Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J Virol 72: 3720-3728.
184. + baboon repopulating cells. Blood 102: 3117-3119.
185. Budak-Alpdogan, T, Banerjee, D and Bertino, JR (2005). Hematopoietic stem cell gene therapy with drug resistance genes: An update. Cancer Gene Ther 12: 849-863.
186. Neff, T, Beard, BC and Kiem, HP (2006). Survival of the fittest: In vivo selection and stem cell gene therapy. Blood 107: 1751-1760.
187. Zaboikin, M, Srinivasakumar, N and Schuening, F (2006). Gene therapy with drug resistance genes. Cancer Gene Ther 13: 335-345.
188. Sawai, N, Zhou, S, Vanin, EF, Houghton, P, Brent TP and Sorrentino, BP (2001). Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 3: 78-87.
189. Jansen, M et al. (2002). Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther 9: 737-746.
190. Persons, DA et al. (2003). Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 102: 506-513.
191. Neff, T et al. (2003). Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 112: 1581-1588.
192. Zielske, SP, Reese, JS, Lingas, KT, Donze, JR and Gerson, SL (2003). In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 112: 1561-1570.
193. Reese, JS, Liu, L and Gerson, SL (2003). Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood 102: 1626-1633.
194. Li, Q, Harju, S and Peterson, KR (1999). Locus control regions: Coming of age at a decade plus. Trends Genet 15: 403-408.
195. Li, Q, Peterson, KR, Fang, X and Stamatoyannopoulos, G (2002). Locus control regions. Blood 100: 3077-3086.
196. Bulger, M, Sawado, T, Schubeler, D and Groudine, M (2002). Chlps of the β-globin locus: Unraveling gene regulation within an active domain. Curr Opin Genet Dev 12: 170-177.
197. Hardison, R, Slightom, JL, Gumucio, DL, Goodman, M, Stojanovic, N and Miller, W (1997). Locus control regions of mammalian β-globin gene clusters: Combining phylogenetic analyses and experimental results to gain functional insights. Gene 205: 73-94.
198. Grosveld, F, van Assendelft, GB, Greaves, DR and Kollias, G (1987). Position-independent, high-level expression of the human β-globin gene in transgenic mice. Cell 51: 975-985.
199. Blom van Assendelft, G, Hanscombe, O, Grosveld, F and Greaves, DR (1989). The β-globin dominant control region activates homologous and heterologous promoters in a tissue-specific manner. Cell 56: 969-977.
200. May, C, Rivella, S, Chadbum, A and Sadelain, M (2002). Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene. Blood 99: 1902-1908.
201. Pawliuk, R et al. (2001). Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294: 2368-2371.
202. Imren, S et al. (2002). Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci USA 99: 14380-14385.
203. Persons, DA, Hargrove, PW, Allay, ER, Hanawa, H and Nienhuis, AW (2003). The degree of phenotypic correction of murine β-thalassemia intermedia following lentiviral-mediated transfer of a human γ-globin gene is influenced by chromosomal position effects and vector copy number. Blood 101: 2175-2183.
204. Rivella, S, May, C, Chadbum, A, Riviere, I and Sadelain, M (2003). A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer. Blood 101: 2932-2939.
205. Levasseur, DN, Ryan, TM, Pawlik, KM and Townes, TM (2003). Correction of a mouse model of sickle cell disease: Lentiviral/antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102: 4312-4319.
206. Hanawa, H, Hargrove, PW, Kepes, S, Srivastava, Dr, Nienhuis, AW and Persons, DA (2004). Extended β-globin locus control region elements promote consistent therapeutic expression of a γ-globin lentiviral vector in murine β-thalassemia. Blood 104: 2281-2290.
207. Puthenveetil, G et al. (2004). Successful correction of the human β-thalassemia major phenotype using a lentiviral vector. Blood 104: 3445-3453.
208. Kowolik, CM, Hu, J and Yee, JK (2001). Locus control region of the human CD2 gene in a lentivirus vector confers position-independent transgene expression. J Virol 75: 4641-4648.
209. + cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood 101: 3416-3423.
210. Gough, PJ and Raines, EW (2003). Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. Blood 101: 485-491.
211. Cui, Y, Golob, J, Kelleher, E, Ye, Z, Pardoll, D and Cheng, L (2002). Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 99: 399-408.
212. Tahara, M et al (2004). Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat Med 10: 835-841.
213. Fire, A (1999). RNA-triggered gene silencing. Trends Genet 15: 358-363.
214. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
215. McCaffrey, AP, Meuse, L, Pham, TT, Conklin, DS, Hannon, GJ and Kay, MA (2002). RNA interference in adult mice. Nature 418: 38-39.
216. Scherer, L and Rossi, JJ (2004). Therapeutic applications of RNA interference: Recent advances in siRNA design. Adv Genet 52: 1-21.
217. III, CR and Chiou, HC (2005). Gene therapy progress and prospects: recent progress in transgene and RNAi expression cassettes. Gene Ther 12: 795-802.
218. Sledz, CA, Holko, M, de Veer, MJ, Silverman, RH and Williams, BR (2003). Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834-839.
219. Pebernard, S and Iggo, RD (2004). Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72: 103-111.
220. Matsumoto, S, Miyagishi, M, Akashi, H, Nagai, R and Taira, K (2005). Analysis of double-stranded RNA-induced apoptosis pathways using interferon-response noninducible small interfering RNA expression vector library. J Biol Chem 280: 25687-25696.
221. Samakoglu, S et al. (2006). A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol 24: 89-94.
222. Levine, BL et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 103: 17372-17377.
223. Lundin, K, Tuukkanen, AM, Jansson, C, Nordstrom, T and Lindqvist, C (2002). No soluble common cytokine receptor gamma chain (gamma(c)) in activated human lymphocyte cultures - comparison with soluble IL-2Rα. Immunol Lett 82: 235-240.
224. Hacein-Bey, H et al. (1996). gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood 87: 3108-3116.
225. Cavazzana-Calvo, M et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
226. Hutton, JJ et al. (1981). Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy. J Clin Invest 68: 413-421.
227. Miller, AD and Rosman, GJ (1989). Improved retroviral vectors for gene transfer and expression. Biotechniques 7: 980-982, 984-986, 989-990.
228. Aiuti, A et al. (2002). Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 8: 423-425.
229. Kolluri, R, Tolias, KF, Carpenter, CL, Rosen, FS and Kirchhausen, T (1996). Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42. Proc Natl Acad Sci USA 93: 5615-5618.
230. Dupre, L et al. (2006). Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther 17: 303-313.
231. Moayeri, M, Hawley, TS and Hawley, RG (2005). Correction of murine hemophilia a by hematopoietic stem cell gene therapy. Mol Ther 12: 1034-1042.
232. Sadelain, M et al. Therapeutic options for patients with severe β-thalassemia: The need for globin gene therapy. Hum Gene Ther, in press.